Expand CLDI Menu
CLDI MENU

CLDI Latest Press Releases

-- April 2, 2026 --

Calidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026 Globe Newswire 8:00 AM

-- April 1, 2026 --

Calidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026 Globe Newswire 8:00 AM

-- March 27, 2026 --

Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights Globe Newswire 4:25 PM

-- March 24, 2026 --

Calidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of CLD-401 Clinical Trials Globe Newswire 8:00 AM

-- March 12, 2026 --

Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company's Approach to Manufacturing Globe Newswire 8:00 AM

-- March 9, 2026 --

Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option Globe Newswire 8:50 PM

-- March 6, 2026 --

Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering Globe Newswire 8:30 AM

-- March 5, 2026 --

Calidi Biotherapeutics Announces Proposed Public Offering Globe Newswire 5:57 PM

-- February 20, 2026 --

Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference Globe Newswire 8:00 AM

-- February 12, 2026 --

Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO Conference Globe Newswire 8:00 AM

-- January 28, 2026 --

Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026 Globe Newswire 8:00 AM

-- November 17, 2025 --

Calidi Biotherapeutics Announces Exclusive Live Investor Webinar and Q&A Session on November 19, 2025 Globe Newswire 8:00 AM

-- November 13, 2025 --

Calidi Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Operational Highlights Globe Newswire 4:15 PM

-- November 10, 2025 --

Calidi Biotherapeutics Presents New Data on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting and Holds Its First Investor Day at SITC Globe Newswire 8:00 AM
Market Data Delayed 15 Minutes